Losartan Potassium
Product Images NDC 71610-241

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 50 mg (71610 0241 30)

Losartan Potassium 50 mg tablets packaging label from Aphena Pharma Solutions - Tennessee, LLC. The label states storage instructions, manufacturing details by Aurobindo Pharma Limited in Hyderabad, India, and distribution by Aphena Pharma in Cookeville, TN. The package contains 30 tablets with NDC 71610-0241.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium and Atenolol. The graph shows cumulative data from 0 to 66 months, indicating an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium relative to Atenolol.*

FDA Label Image

Figure2 (Losartan Fig2)

A comparative line graph showing the percentage of patients with fatal or non-fatal stroke over time (study months) for Atenolol and Losartan Potassium. The graph illustrates adjusted risk reduction for Losartan Potassium at 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol event rates. The chart presents hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) events across various demographic categories including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The hazard ratio axis ranges from 0.3 to 3, indicating relative event risks favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph depicting the percentage of patients with an event over 48 months, comparing Losartan Potassium (solid line) versus placebo (dashed line). The graph shows a risk reduction of 16.1% with Losartan Potassium and a statistical significance of p=0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of the active ingredient Losartan Potassium, showing its molecular configuration including the potassium (K+) ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.